Galectin Therapeutics (NASDAQ:GALT) Releases Earnings Results, Misses Estimates By $0.03 EPS

Galectin Therapeutics (NASDAQ:GALT) posted its quarterly earnings data on Monday. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03), Zacks reports.

Galectin Therapeutics Trading Up 3.3 %

GALT stock opened at $1.26 on Wednesday. The stock has a market cap of $79.08 million, a price-to-earnings ratio of -1.73 and a beta of 0.69. Galectin Therapeutics has a 1-year low of $0.73 and a 1-year high of $4.27. The company’s 50 day moving average is $1.45 and its 200 day moving average is $1.95.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Galectin Therapeutics stock. Bank of America Corp DE raised its stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 101.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 38,358 shares of the company’s stock after acquiring an additional 19,316 shares during the period. Bank of America Corp DE owned approximately 0.06% of Galectin Therapeutics worth $49,000 as of its most recent SEC filing. Institutional investors own 11.68% of the company’s stock.

Analysts Set New Price Targets

GALT has been the topic of a number of recent analyst reports. HC Wainwright reissued a “neutral” rating on shares of Galectin Therapeutics in a research note on Wednesday. StockNews.com lowered shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, December 30th.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.